Atopic Dermatitis

Roflumilast cream 0.05% is being studied for mild to moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate to severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.

The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.

Results at 24 weeks revealed that 76% of individuals achieved a 75% or more improvement in overall disease severity (EASI-75), trial's primary endpoint.

Mona Shahriari, MD, discusses how RAD 2025 can equip providers with tools to improve atopic dermatitis outcomes.

View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Peter Lio, MD, offers thoughts on recent atopic dermatitis data reported for lebrikizumab.

The newest tapinarof results were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.

Lebrikizumab improves itch, sleep interference, and skin pain in atopic dermatitis patients previously treated with dupilumab, offering a new treatment option.

The application is for children aged 2 to 5 years with mild-to-moderate atopic dermatitis.

Nearly 40% of children treated with roflumilast cream 0.05% achieved a 75% improvement in EASI-75.

The investigational biologic targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The past year saw a number of approvals adding to the toolbox for atopic dermatitis, including new formulations that work in new mechanisms.

Russell Libby, MD, FAAP highlights some key benefits of roflumilast 0.15%, approved in 2024 to treat AD in patients aged 6 years and older.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

"Tapinarof comes in with that mixture of the short-term studies and longer-term studies intermittently, giving us a nice, effective alternative non-steroid for eczema across the ages."

From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024.

Arcutis seeks FDA approval for roflumilast cream 0.05% (ZORVYE) to treat mild to moderate atopic dermatitis in children 2 to 5 years.

According to Galderma, approval is based on positive results from the phase 3 ARCADIA clinical trial program.

"I really hope this becomes a first-line agent that people are comfortable prescribing whether they are in dermatology, pediatric dermatology, or primary care."

In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).

The submission to treat PsO is for children aged 6 years and up while the jPsA submission is to treat children aged 5 years and older.